New mRNA vaccine takes aim at RSV in early human trial

NCT ID NCT06645665

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IN006 bivalent mRNA vaccine
What this could lead to: If successful, this could lead to a new vaccine option to protect against respiratory syncytial virus (RSV) infections.
What could go wrong: This is a very early Phase 1 trial with only 240 participants, so safety and effectiveness are not yet proven. The vaccine may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory tract infectious disorder viral infectious disease respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Show contact details

Locations

Anning First People's Hospital

Kunming, Yunnan, China
Huashan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.